trending Market Intelligence /marketintelligence/en/news-insights/trending/Zrl4_JX5IK_GLd_E7oqgDQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Thermo Fisher Q3 profit up 11.4%; full-year outlook raised anew

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Thermo Fisher Q3 profit up 11.4%; full-year outlook raised anew

Thermo Fisher Scientific Inc. said its third-quarter profit increased 11.4% and raised its revenue and earnings outlook for 2019 again.

The Waltham, Mass.-based medical-device maker booked third-quarter adjusted net income of $1.19 billion, or $2.94 per share, up from $1.07 billion, or $2.62 per share, in the year-ago period.

The S&P Global Market Intelligence consensus normalized EPS estimate for the quarter was $2.89.

Revenues for the quarter grew 6% year over year to $6.27 billion from $5.92 billion. Research and development expenses were $247 million, a 2.9% increase from $240 million a year earlier.

On a GAAP basis, net income rose 7.2% to $760 million, or $1.88 per share, from $709 million, or $1.75 per share.

For the first nine months of 2019, Thermo Fisher said its adjusted net income reached $3.55 billion, or $8.80 per share, up 11.1% from $3.19 billion, or $7.87 per share, in the same year-ago period.

Revenues for the nine months ended Sept. 30 were $18.71 billion, a 4.8% increase from $17.85 billion, in 2018.

Nine-month GAAP net income came in at $2.69 billion, or $6.68 per share, up 32.1% from $2.04 billion, or $5.03 per share, a year earlier.

Thermo Fisher further raised its revenue and earnings guidance for the full year, citing its stronger operational performance and refinancing activities. The company slightly increased its revenue guidance in the range of $25.34 billion to $25.50 billion, from the prior outlook of $25.30 billion to $25.50 billion.

In addition, the medical-device maker expects adjusted EPS in the range of $12.28 to $12.34, reflecting a 10% to 11% growth year over year. The company previously estimated its adjusted EPS to be in the range of $12.16 to $12.26.

The S&P Global Market Intelligence consensus normalized EPS estimate for 2019 is $12.26.

Thermo Fisher Scientific provides instruments, equipment, software and services for life science research.